CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Governance Charles River Laboratories International, Inc.

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 21:00:02 13/06/2025 BST			5-day change	1st Jan Change
149.45 ^USD	-1.61%		+3.28%	-19.04%

06-09	Charles River Laboratories International, Inc. Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 10:00 AM
06-04	Charles River Laboratories International, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 10:30 AM

Executive Committee: Charles River Laboratories International, Inc.

Manager

Positions heldSince

James Foster

74 year

Chief Executive Officer	31/12/1991
President	31/12/1990

Victoria Creamer

55 year

Human Resources Officer

31/12/2018

Julie Frearson

Chief Tech/Sci/R&D Officer

31/12/2013

Mark Mintz

Chief Tech/Sci/R&D Officer

31/01/2021

Flavia Pease

52 year

Director of Finance/CFO

30/04/2022

Todd Spencer

Investor Relations Contact

31/05/2018

Michael Knell

48 year

Comptroller/Controller/Auditor

25/04/2017

Gina Mullane

Sales & Marketing

31/12/2015

Birgit Girshick

55 year

Chief Operating Officer

10/11/2021

Matthew Daniel

Compliance Officer	31/12/2010
General Counsel	31/12/2010
Corporate Secretary	31/12/2019

Composition of the Board of Directors: Charles River Laboratories International, Inc.

Director

CommitteesSince

James Foster

74 year

Chairman

31/12/1999

Virginia Wilson

69 year

Compensation Committee	30/09/2019
Governance Committee	30/09/2019
Nominating Committee	30/09/2019
Audit Committee Chair
Audit Committee	31/12/2019
Governance Committee Chair

Nancy Andrews

66 year

Governance Committee Chair	19/05/2025
Nominating Committee Chair	19/05/2025
Compensation Committee	31/01/2021

George Llado

59 year

Audit Committee
Governance Committee	15/10/2020
Nominating Committee	15/10/2020

Mark Enyedy

61 year

Audit Committee	26/12/2023
Governance Committee	19/05/2025
Nominating Committee	19/05/2025

Martin MacKay

68 year

Finance Committee
Compensation Committee	28/07/2024

Abraham Ceesay

47 year

Audit Committee	27/01/2025
Compensation Committee	09/10/2023

Paul Graves

54 year

Audit Committee

19/05/2025

Reshema Kemps-Polanco

52 year

Compensation Committee Chair

19/05/2025

Steven Barg

63 year

Compensation Committee

19/05/2025

Craig Thompson

72 year

Director/Board Member	04/12/2022
Independent Dir/Board Member	04/12/2022

Latest Appointments: Charles River Laboratories International, Inc.

Charles River raises 2025 profit forecast, reaches deal with activist investor	05-07	RE
Charles River Laboratories International, Inc. Announces Board Changes	05-07	CI
Charles River to add new directors, review business in agreement with Elliott	05-07	RE
Surgical Innovations profit boosted in second half, names new CFO	02-12	AN
Charles River Laboratories International, Inc. Appoints Reshema Kemps-Polanco to Board of Directors	24/01/24	CI
Charles River Laboratories International, Inc. Announces Executive Changes	16/01/24	CI
Charles River Laboratories International, Inc. Appoints Craig B. Thompson to the Board	06/12/22	CI

More news

Former Officers and Directors: Charles River Laboratories International, Inc.

Insider

Positions held

SinceUntil

Richard Wallman

Director/Board Member	23/01/2011	19/05/2025
Independent Dir/Board Member	23/01/2011	19/05/2025

Deborah Kochevar

Director/Board Member	28/10/2008	19/05/2025
Independent Dir/Board Member	28/10/2008	19/05/2025

George Massaro

Director/Board Member	31/12/2002	19/05/2025
Independent Dir/Board Member	31/12/2002	19/05/2025

Robert Bertolini

Director/Board Member	24/01/2011	19/05/2025
Independent Dir/Board Member	24/01/2011	19/05/2025

William Barbo

Corporate Officer/Principal	30/09/2016	31/12/2024
Sales & Marketing	31/12/2009	30/09/2016

C. Reese

Director/Board Member	02/12/2007	07/05/2024
Independent Dir/Board Member	02/12/2007	07/05/2024

Barbara Patterson

Compliance Officer	31/12/2011	30/11/2023
General Counsel	31/12/2015	30/11/2023

Steven Coen

Comptroller/Controller/Auditor

30/04/2017

30/04/2023

George Milne

Director/Board Member	31/12/2001	09/05/2022
Trading-Equity	31/12/2001	31/12/2001
Independent Dir/Board Member	31/12/2001	09/05/2022

David Smith

Comptroller/Controller/Auditor	30/10/2016	25/04/2017
Director of Finance/CFO	30/10/2016	30/04/2022
Corporate Officer/Principal	31/03/2014	30/10/2016

Christine Pelletier

Human Resources Officer

31/03/2019

31/01/2021

John Kuo

Compliance Officer	30/04/2020	31/08/2020
General Counsel	30/04/2020	31/08/2020
Corporate Secretary	30/04/2020	31/08/2020

David Patrick Johst

Chief Administrative Officer	31/12/1990	30/05/2020
Human Resources Officer	18/04/2010	14/12/2011
General Counsel	14/04/2010	30/05/2020
Corporate Secretary	03/05/2009	30/05/2020

Jean-Paul Mangeolle

Director/Board Member	14/01/2018	05/05/2020
Independent Dir/Board Member	14/01/2018	05/05/2020

Shanna Cotti-Osmanski

Chief Tech/Sci/R&D Officer

31/12/2005

31/12/2019

Davide A. Molho

Chief Operating Officer	12/02/2018	01/08/2018
Corporate Officer/Principal	02/07/2009	12/02/2018
President	12/02/2018	01/08/2018

Susan E. Hardy

Investor Relations Contact

30/05/2018

Grace Lee

Human Resources Officer

31/12/2015

31/12/2017

John Crowley

Comptroller/Controller/Auditor

29/09/2013

31/10/2016

Nancy A. Gillett

Chief Tech/Sci/R&D Officer	23/08/2011	06/03/2016
Corporate Officer/Principal	31/08/1999	23/08/2011

Thomas Ackerman

Director of Finance/CFO	31/12/1995	11/08/2015
Corporate Officer/Principal	31/12/1991	31/12/1995

Arthur Hubbs

Chief Tech/Sci/R&D Officer	30/04/2010	31/07/2015
Chief Tech/Sci/R&D Officer	31/12/2019	-

Emily Hickey

Corporate Officer/Principal

30/09/2013

Samuel O. Thier

Director/Board Member	31/12/1999	06/05/2013
Independent Dir/Board Member	31/12/1999	06/05/2013

William H. Waltrip

Director/Board Member	31/12/1995	06/05/2013
Director of Research - Equity	31/12/1995	31/12/1995
Independent Dir/Board Member	31/12/1995	06/05/2013

Nancy Chang

Director/Board Member

23/10/2007

23/01/2011

Real H. Renaud

Corporate Officer/Principal

31/12/1963

30/12/2010

Cheri Walker

Corporate Officer/Principal

31/03/2007

Stephanie B. Wells

Sales & Marketing

11/03/2007

Nicholas Ventresca

Chief Tech/Sci/R&D Officer

31/03/2006

Stephen K. Durham

Corporate Officer/Principal

03/01/2011

David J. Elliott

Comptroller/Controller/Auditor

30/09/2005

S. Louise McCrary

Director/Board Member

24/02/2005

Robert Cawthorn

Director/Board Member

31/12/1998

24/02/2005

John Urquhart

Director/Board Member

31/12/2003

31/12/2004

Joanne P. Acford

General Counsel	30/11/2004	-
Corporate Secretary	30/11/2004	-

Christopher J. Perkin

Corporate Officer/Principal

30/09/2004

Linda McGoldrick

Director/Board Member

31/12/2003

Joseph C. Siglin

Corporate Officer/Principal

03/01/2011

Douglas E. Rogers

Director/Board Member	31/12/1998	31/12/2000
Director/Board Member	03/05/2009	23/01/2011

Stephen D. Chubb

Director/Board Member	31/12/1993	-
Independent Dir/Board Member	31/12/1993	-

Jörg M. Geller

Corporate Officer/Principal

31/12/1985

Alastair Stuart McEwan

Corporate Officer/Principal

Michael F. Ankcorn

Corporate Officer/Principal

Walter S. Nimmo

Director/Board Member

William H. Eagan

Treasurer

31/12/2006

Andy Self

Corporate Officer/Principal

Thompson Dean

Director/Board Member

Joel McComb

Corporate Officer/Principal

John Beattie

Corporate Officer/Principal

John Montana

Corporate Officer/Principal

Dennis R. Shaughnessy

General Counsel	-	-
Corporate Secretary	-	-

Karen A. Blomquist

Public Communications Contact

Susan Desmond

Corporate Officer/Principal

Kitty Sahin

Corporate Officer/Principal

Henry L. Foster

Founder

31/12/1946

Age distribution of managers

Parity Men Women

Male	19
Female	9

Of which Executive Committee

Male	6
Female	4

Of which Directors

Male	9
Female	2

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

ESG MSCI

ESG

ESG: Environment

ESG: Social

ESG: Governance

ESG: Controversy

ESG: Ethical controversies

ESG: Human rights controversies

ESG: Tax subsidies controversies

ESG: Sharia compliant

Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (60.5%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (20.5%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (81.6%) and sales of products (18.4%). Net sales are distributed geographically as follows: the United States (55.3 Europe (26.6%), Canada (11.9%), Asia/Pacific (4.9%) and other (1.3%).

Employees

19,400

Sector

Biotechnology & Medical Research

Calendar

07-29 - Q2 2025 Earnings Release (Projected)

More about the company